Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.
Adriamycin (doxorubicin), a potent antitumor drug in clinical use, interacts with nucleic acids and cell membranes, but the molecular basis for its antitumor activity is unknown. Similar to a number of intercalative antitumor drugs and nonintercalative epipodophyllotoxins (VP-16 and VM-26), adriamycin has been shown to induce single- and double-strand breaks in DNA. These strand breaks are unusual because a covalently bound protein appears to be associated with each broken phosphodiester bond. In studies in vitro, mammalian DNA topoisomerase II mediates DNA damage by adriamycin and other related antitumor drugs.
D000255:Adenosine Triphosphate / Q000494:pharmacology; D004247:DNA; D004264:DNA Topoisomerases, Type I / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology*; D012965:Sodium Chloride / Q000494:pharmacology
D012965:Sodium Chloride; D004317:Doxorubicin; D000255:Adenosine Triphosphate; D004247:DNA; D004264:DNA Topoisomerases, Type I